Amgen (AMGN) Stock Forecast & Price Target

$316.04 +1.00 (+0.32%)

Closing price 03/21/2025 04:00 PM Eastern

Extended Trading

$315.82 -0.22 (-0.07%)

As of 03/21/2025 07:58 PM Eastern

Amgen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 24 Analyst Ratings

Sell
2

Hold
10

Buy
12

Based on 24 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 2 have given a sell rating, 10 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for AMGN.

Consensus Price Target

$314.04
-0.63% Downside

According to the 24 analysts' twelve-month price targets for Amgen, the average price target is $314.04. The highest price target for AMGN is $405.00, while the lowest price target for AMGN is $195.00. The average price target represents a forecasted downside of -0.63% from the current price of $316.04.

Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

AMGN Analyst Ratings Over Time

Type	Current Forecast 3/24/24 to 3/24/25	1 Month Ago 2/23/24 to 2/22/25	3 Months Ago 12/25/23 to 12/24/24	1 Year Ago 3/25/23 to 3/24/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)
Hold	10 Hold rating(s)	10 Hold rating(s)	12 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$314.04	$314.09	$319.67	$295.30
Forecasted Upside	-0.63% Downside	3.66% Upside	20.86% Upside	6.93% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Remove Ads

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amgen Stock vs. The Competition

Type	Amgen	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.82	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-0.63% Downside	21,753.34% Upside	18.90% Upside
News Sentiment Rating	Very Positive News See Recent AMGN News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/5/2025	Johnson Rice 4 of 5 stars		Set Target		$294.00	-10.47%
3/5/2025	Bank of America 4 of 5 stars	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underperform ➝ Underperform	$275.00 ➝ $294.00	-6.90%
2/12/2025	UBS Group 4 of 5 stars		Reiterated Rating	Hold ➝ Hold
2/10/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Amsellem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$310.00 ➝ $329.00	+12.08%
2/5/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight
2/5/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
1/24/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$324.00 ➝ $324.00	+17.55%
1/8/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$333.00 ➝ $298.00	+13.71%
1/2/2025	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	$310.00	+18.94%
11/27/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$305.00 ➝ $285.00	+1.78%
The Dirty Secret About Gold Mining Stocks... (Ad) Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise. Right now, I've found 4 miners showing the exact same pattern as previous 100-baggers.
11/27/2024	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$200.00 ➝ $195.00	-30.36%
11/27/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$349.00 ➝ $302.00	+7.85%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/12/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$380.00 ➝ $380.00	+28.07%
11/12/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/22/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$405.00 ➝ $405.00	+28.41%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$381.00 ➝ $383.00	+20.14%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$380.00	+18.15%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$300.00 ➝ $315.00	-0.48%
9/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform ➝ Underperform	$215.00 ➝ $215.00	-31.92%
9/16/2024	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$380.00 ➝ $380.00	+22.53%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$310.00 ➝ $303.00	-6.67%
6/27/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$300.00 ➝ $340.00	+8.87%
5/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$223.00 ➝ $235.00	-23.53%
5/3/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$336.00 ➝ $355.00	+12.91%
3/28/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
2/7/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$313.00 ➝ $350.00	+10.73%
12/21/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$264.00 ➝ $320.00	+16.29%
10/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$270.00	-3.69%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$320.00	+25.98%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$220.00 ➝ $200.00	-10.66%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:42 AM ET.

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, March 19, 2025. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

Here are some ways that investors could benefit from investing in Amgen Inc.:

Amgen Inc. has a strong dividend yield of 3.00%, providing investors with a reliable income stream. The recent dividend of $2.38 per share reflects the company's commitment to returning value to shareholders.
The stock is currently priced at $318.65, which is near its 1-year high of $346.85, indicating strong market performance and investor confidence.
Analysts have a consensus rating of "Hold" with an average target price of $314.04, suggesting that there is potential for price appreciation based on current valuations.
Amgen Inc. has a diverse portfolio of innovative therapeutics, including recent advancements in treatments for conditions like osteoporosis and multiple myeloma, which can drive future revenue growth.
The company has received positive ratings from multiple analysts, with Piper Sandler recently raising its price target to $329.00, indicating optimism about the company's future performance.

Amgen
Bear Case

Investors should be bearish about investing in Amgen Inc. for these reasons:

Amgen Inc. has a high dividend payout ratio of 126.09%, which may raise concerns about the sustainability of its dividend payments in the long term.
Insider selling has been notable, with executives selling a total of 69,341 shares valued at over $20 million in the last 90 days, which could signal a lack of confidence in the stock's future performance.
The company has a relatively high debt-to-equity ratio of 9.62, indicating that it relies heavily on debt financing, which can be risky in volatile market conditions.
Despite a strong product lineup, the competitive landscape in the biopharmaceutical industry is intense, and any setbacks in product development could negatively impact the company's market position.
Recent stock performance has shown volatility, with fluctuations around its 50-day and 200-day moving averages, which may deter risk-averse investors.

AMGN Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $314.04, with a high forecast of $405.00 and a low forecast of $195.00.
: 24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 10 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
: According to analysts, Amgen's stock has a predicted downside of -0.63% based on their 12-month stock forecasts.
: Amgen has been rated by research analysts at Bank of America, Citigroup, Johnson Rice, Piper Sandler, Piper Sandler Companies, Royal Bank of Canada, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Amgen less than other "medical" companies. The consensus rating for Amgen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:AMGN) was last updated on 3/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amgen (AMGN) Stock Forecast & Price Target